Bath & Body Works, Inc. (NYSE:BBWI) Position Trimmed by Amundi

Amundi cut its position in shares of Bath & Body Works, Inc. (NYSE:BBWI - Free Report) by 92.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 36,287 shares of the company's stock after selling 428,923 shares during the quarter. Amundi's holdings in Bath & Body Works were worth $1,342,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC grew its holdings in shares of Bath & Body Works by 17,496.5% during the third quarter. FMR LLC now owns 2,516,127 shares of the company's stock worth $80,315,000 after buying an additional 2,501,828 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Bath & Body Works by 13.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,704,625 shares of the company's stock worth $66,088,000 after acquiring an additional 195,813 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Bath & Body Works in the third quarter worth approximately $50,483,000. Forest Avenue Capital Management LP boosted its position in shares of Bath & Body Works by 19.1% in the third quarter. Forest Avenue Capital Management LP now owns 1,467,763 shares of the company's stock worth $46,851,000 after acquiring an additional 235,173 shares during the last quarter. Finally, Verition Fund Management LLC boosted its position in shares of Bath & Body Works by 111.8% in the third quarter. Verition Fund Management LLC now owns 1,345,777 shares of the company's stock worth $42,957,000 after acquiring an additional 710,333 shares during the last quarter. 95.14% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Bath & Body Works Stock Up 0.5 %

Shares of NYSE BBWI traded up $0.14 during trading on Friday, reaching $30.24. 42,058,293 shares of the stock were exchanged, compared to its average volume of 4,241,127. The business's 50-day moving average price is $35.70 and its 200 day moving average price is $33.93. Bath & Body Works, Inc. has a twelve month low of $26.21 and a twelve month high of $52.99. The company has a market capitalization of $6.48 billion, a price-to-earnings ratio of 7.38, a price-to-earnings-growth ratio of 0.92 and a beta of 1.89.

Bath & Body Works (NYSE:BBWI - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $2.09 EPS for the quarter, topping analysts' consensus estimates of $2.04 by $0.05. Bath & Body Works had a net margin of 12.43% and a negative return on equity of 44.03%. The business had revenue of $2.79 billion for the quarter, compared to analysts' expectations of $2.78 billion. As a group, sell-side analysts expect that Bath & Body Works, Inc. will post 3.3 earnings per share for the current fiscal year.

Bath & Body Works Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, February 21st were paid a $0.20 dividend. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 2.65%. Bath & Body Works's dividend payout ratio (DPR) is presently 21.98%.

Bath & Body Works announced that its Board of Directors has initiated a share repurchase program on Thursday, February 27th that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the company to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Telsey Advisory Group reissued an "outperform" rating and issued a $43.00 target price on shares of Bath & Body Works in a research report on Thursday, February 27th. Robert W. Baird raised their target price on shares of Bath & Body Works from $45.00 to $47.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. TD Cowen raised their target price on shares of Bath & Body Works from $42.00 to $48.00 and gave the stock a "buy" rating in a research report on Thursday, December 12th. Raymond James reissued an "outperform" rating and issued a $46.00 target price (up from $42.00) on shares of Bath & Body Works in a research report on Tuesday, February 25th. Finally, Barclays reduced their price target on shares of Bath & Body Works from $43.00 to $38.00 and set an "equal weight" rating on the stock in a research report on Monday, March 3rd. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, Bath & Body Works has an average rating of "Moderate Buy" and an average price target of $45.06.

About Bath & Body Works

Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.